SARS-CoV-2-IN-110
SARS-CoV-2-IN-110 (compound Bb1) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-110 exhibits antiviral efficacy against SARS-CoV-2 with an EC50 of 1.10 μM and significantly lower toxicity compared to Lapatinib (HY-50898) . SARS-CoV-2-IN-110 inhibits SARS-CoV-2 with a CC50 of > 100 μM, with a selectivity index (SI) of >91[1].
Product Specifications
UNSPSC
12352005
Target
SARS-CoV
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Smiles
ClC1=CC(NC2=NC=NC3=CC=CC=C32)=CC=C1OCC4=CC(C(NC5=CC=CC=C5F)=O)=CC=C4
Molecular Formula
C28H20ClFN4O2
Molecular Weight
498.94
References & Citations
[1]Adediji A, et al. Design, synthesis, and antiviral activity of fragmented-lapatinib aminoquinazoline analogs towards SARS-CoV-2 inhibition. Eur J Med Chem. 2025 Mar 15;286:117303.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
